MX2011009757A - Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. - Google Patents
Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico.Info
- Publication number
- MX2011009757A MX2011009757A MX2011009757A MX2011009757A MX2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A
- Authority
- MX
- Mexico
- Prior art keywords
- ursodeoxycholic acid
- nonalcoholic steatohepatitis
- treating nonalcoholic
- elevated doses
- treatment
- Prior art date
Links
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 title abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 title abstract 3
- 229960001661 ursodiol Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16095509P | 2009-03-17 | 2009-03-17 | |
| PCT/IB2010/000551 WO2010106420A1 (en) | 2009-03-17 | 2010-03-16 | Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009757A true MX2011009757A (es) | 2012-02-28 |
Family
ID=42167374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009757A MX2011009757A (es) | 2009-03-17 | 2010-03-16 | Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120071451A1 (enExample) |
| EP (1) | EP2408457A1 (enExample) |
| JP (1) | JP2012520866A (enExample) |
| KR (1) | KR20120008034A (enExample) |
| CN (1) | CN102361642A (enExample) |
| AU (1) | AU2010224587A1 (enExample) |
| CA (1) | CA2755708A1 (enExample) |
| IL (1) | IL215195A0 (enExample) |
| MX (1) | MX2011009757A (enExample) |
| RU (1) | RU2011139643A (enExample) |
| WO (1) | WO2010106420A1 (enExample) |
| ZA (1) | ZA201107578B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| KR101401628B1 (ko) * | 2012-12-24 | 2014-06-02 | 삼성제약공업주식회사 | 간기능 개선용 정제 및 그 제조 방법 |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| CN110179792A (zh) * | 2014-07-29 | 2019-08-30 | 深圳君圣泰生物技术有限公司 | 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用 |
| WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| US10925854B2 (en) * | 2015-11-19 | 2021-02-23 | Sinew Pharma Inc. | Methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders |
| CA3016641A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| KR102546194B1 (ko) | 2016-11-04 | 2023-06-21 | 칠드런즈 호스피탈 메디칼 센터 | 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법 |
| KR102807995B1 (ko) | 2016-12-05 | 2025-05-16 | 칠드런즈 호스피탈 메디칼 센터 | 결장 유사장기 및 이를 제조 및 사용하는 방법 |
| JP7248586B2 (ja) | 2017-04-14 | 2023-03-29 | チルドレンズ ホスピタル メディカル センター | 複数ドナー幹細胞組成物およびそれを作製する方法 |
| US11179364B2 (en) * | 2017-06-21 | 2021-11-23 | Novartis Ag | Licofligozin for the treatment of non-alcoholic steatohepatitis |
| WO2019074793A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME |
| KR101887561B1 (ko) * | 2017-11-15 | 2018-09-06 | 주식회사 대웅제약 | 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물 |
| WO2019126626A1 (en) | 2017-12-21 | 2019-06-27 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| RU2686042C1 (ru) * | 2018-09-04 | 2019-04-23 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Способ лечения неалкогольной жировой болезни печени при метаболическом синдроме |
| US12428622B2 (en) | 2018-09-12 | 2025-09-30 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| JP7303372B2 (ja) * | 2019-07-30 | 2023-07-04 | コバイオラブス，インコーポレーテッド | 肝損傷予防、改善、または治療用組成物、および肝損傷予防、改善、または治療方法 |
| KR102395036B1 (ko) * | 2019-07-30 | 2022-05-09 | 주식회사 고바이오랩 | 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 진단방법 |
| PH12022551256A1 (en) * | 2020-01-28 | 2023-11-20 | Shilpa Medicare Ltd | Method for administration of ursodeoxycholic acid |
| EP4232045A4 (en) * | 2020-10-23 | 2024-09-04 | Shenzhen Hightide Biopharmaceutical Ltd. | BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND RELATED METHODS FOR THE TREATMENT OF FATTY LIVER, DIABETES AND HYPERLIPIDEMIA |
| CN115137732A (zh) * | 2021-03-29 | 2022-10-04 | 中国科学院大连化学物理研究所 | Gpr120受体激动剂及熊去氧胆酸的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297229B1 (en) * | 1994-11-14 | 2001-10-02 | Mayo Foundation For Medical Education And Research | Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis |
-
2010
- 2010-03-16 KR KR1020117024296A patent/KR20120008034A/ko not_active Withdrawn
- 2010-03-16 JP JP2012500328A patent/JP2012520866A/ja active Pending
- 2010-03-16 AU AU2010224587A patent/AU2010224587A1/en not_active Abandoned
- 2010-03-16 WO PCT/IB2010/000551 patent/WO2010106420A1/en not_active Ceased
- 2010-03-16 CN CN2010800119928A patent/CN102361642A/zh active Pending
- 2010-03-16 EP EP10714958A patent/EP2408457A1/en not_active Ceased
- 2010-03-16 MX MX2011009757A patent/MX2011009757A/es not_active Application Discontinuation
- 2010-03-16 CA CA2755708A patent/CA2755708A1/en not_active Abandoned
- 2010-03-16 RU RU2011139643/15A patent/RU2011139643A/ru not_active Application Discontinuation
-
2011
- 2011-08-24 US US13/217,042 patent/US20120071451A1/en not_active Abandoned
- 2011-09-18 IL IL215195A patent/IL215195A0/en unknown
- 2011-10-17 ZA ZA2011/07578A patent/ZA201107578B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL215195A0 (en) | 2011-12-29 |
| KR20120008034A (ko) | 2012-01-25 |
| CA2755708A1 (en) | 2010-09-23 |
| RU2011139643A (ru) | 2013-04-27 |
| JP2012520866A (ja) | 2012-09-10 |
| WO2010106420A1 (en) | 2010-09-23 |
| CN102361642A (zh) | 2012-02-22 |
| AU2010224587A1 (en) | 2011-09-22 |
| EP2408457A1 (en) | 2012-01-25 |
| ZA201107578B (en) | 2013-06-26 |
| US20120071451A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009757A (es) | Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. | |
| MX362626B (es) | Métodos para tratar pacientes pediátricos usando dexmedetomidina.. | |
| MX2016005532A (es) | Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades. | |
| SG179027A1 (en) | Dosage regimen for administering an epcamxcd3 bispecific antibody | |
| EA201190337A1 (ru) | Способ лечения | |
| MX2012007875A (es) | Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares. | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| PH12013500559A1 (en) | Combination therapy for treating hcv infection | |
| EP2418956A4 (en) | METHOD FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| MX357556B (es) | Composiciones acuosas que comprenden arbekacina. | |
| RU2013104381A (ru) | Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf | |
| MX2012013374A (es) | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. | |
| WO2011133826A3 (en) | Method for treating pancreatic cancer | |
| WO2011056850A3 (en) | Linaclotide for the treatment of chronic constipation | |
| WO2012012304A3 (en) | Method of treating refractory cancer | |
| WO2011072181A3 (en) | Method of treating pancreatic cancer | |
| WO2011133827A3 (en) | Method of treating prostate cancer | |
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| WO2012075210A3 (en) | Method for treating refractory cancer | |
| MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
| WO2011139867A3 (en) | Method of treating brain cancer | |
| UA59667U (ru) | Способ медицинской реабилитации больных неалкогольным стеатогепатитом с использованием средств антигомотоксической терапии | |
| UA69684U (ru) | Способ медицинской реабилитации больных неалкогольным стеатогепатитом, соединенным с дисбиозом кишечника | |
| UA65525U (ru) | Способ лечения больных ишемической болезнью сердца | |
| BR112014014968A2 (pt) | tratamento contra seborréia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |